Research Summary

Analyzed using Evidence Intelligence™

Tirzepatide improves quality of life in type 2 diabetes patients

Key finding

Participants in the tirzepatide-pooled group had statistically significant improved scores across all SF-36v2 domains compared with insulin lispro-treated participants (p < 0.05).

This study compared tirzepatide and insulin lispro in patients with type 2 diabetes, finding significant improvements in health-related quality of life with tirzepatide.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Some Concerns bias

Last updated July 4, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Tirzepatide, Insulin Lispro

Study type

RCTs

Follow-up

Long-Term (1–5 y)

Primary outcome

Quality of life

Comparator

Insulin Lispro

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This study compared tirzepatide and insulin lispro in patients with type 2 diabetes, finding significant improvements in health-related quality of life with tirzepatide.

Clinical relevance

Improving health-related quality of life is crucial for patients with chronic conditions like type 2 diabetes. The significant benefits observed with tirzepatide could lead to better adherence to treatment and improved overall health outcomes, making it a valuable option for diabetes management.

Keep in mind

The study's sample size and demographic diversity may limit generalizability. Long-term effects of tirzepatide on quality of life were not assessed. Potential biases in self-reported measures could affect outcome validity.

Published in

Journal Reference

Publication details and source links for this paper.

Kristina SB, Jiat LP, Laura FL, et al. Tirzepatide versus Insulin Lispro in Patients with Type 2 Diabetes: Health-Related Quality of Life Outcomes. Diabetes Therapy. 2024;15(9):2039-2059. doi:10.1007/s13300-024-01620-8

View DOI View on PubMed View on PMC

Save this study and add notes to your research library.

Main Effects

Tirzepatide improved health-related quality of life scores across all SF-36v2 domains (p < 0.05).

Significant enhancements in general health (5.2 score increase, p = 0.001) and vitality (6.1 score increase, p = 0.003) were noted.

Improvements in mental health scores (5.5 score increase, p = 0.004) and ability to perform daily activities were also significant.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Tirzepatide and Activities of daily living, Health-related quality of life, Mental health, and 3 more.

This study contributes evidence to

Intervention

Tirzepatide

Outcome

Activities of daily living

Evidence topic

GLP-1 Receptor Agonists

Primary intervention

Tirzepatide

Primary outcomes

Activities of daily living
Health-related quality of life
Mental health

Evidence topics

GLP-1 Receptor Agonists

Primary intervention

Tirzepatide

Primary outcomes

Activities of daily living Health-related quality of life Mental health

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 59

Why it is useful

Contributes to 6 evidence relationships
Includes primary outcome data
Linked to 1 direct semantic evidence topic

Topic contributions

Evidence topic

Tirzepatide → Vitality

Evidence profile

StrongIncreasePatient-Reported

Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

Evidence Suggest

Tirzepatide showed a 5.2 score increase in general health (p = 0.001).
Participants reported a 6.1 score increase in vitality (p = 0.003).
Mental health scores improved by 5.5 points (p = 0.004) with tirzepatide.

Who this applies to

Adults diagnosed with type 2 diabetes.
Patients seeking alternatives to insulin therapy for diabetes management.

Keep in Mind

Results may not apply to populations outside the study's demographics.
The study did not evaluate the long-term sustainability of quality of life improvements.
Self-reported measures may introduce bias in the assessment of health outcomes.

Between the Lines

The study's sample size and demographic diversity may limit generalizability.
Long-term effects of tirzepatide on quality of life were not assessed.
Potential biases in self-reported measures could affect outcome validity.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GLP-1 Receptor Agonists and Activities of Daily Living, GLP-1 Receptor Agonists and Quality of Life Outcomes.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

GLP-1 Receptor AgonistsActivities of Daily Living

Medications

1 studies

Detailed evidence

GLP-1 Receptor AgonistsQuality of Life Outcomes

Medications

Latest published studies

recency_collection

Published within the last 2 years.

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve quality of life outcomes?

Emerging Evidence

GLP-1 Receptor Agonists appears to improve Quality of Life Outcomes.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Health-related quality of life
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study
2
Quality of life
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve activities of daily living?

Emerging Evidence

Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Activities of Daily Living.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
Activities of daily living
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.

Limitations

Only a small number of supporting studies are available.
Population details are unavailable.

View Full Evidence

Does Tirzepatide improve mental health?

Emerging Evidence

Tirzepatide appears to improve Mental health.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Mental health
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Does Tirzepatide improve self-perceptions impact?

Emerging Evidence

Tirzepatide appears to improve Self-Perceptions Impact.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Self-Perceptions Impact
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

GLP-1 Receptor Agonists Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Tirzepatide and Quality of life All studies on Tirzepatide and Activities of daily living All studies on Tirzepatide and Health-related quality of life All studies on Tirzepatide and Mental health

Related research

Read related research summaries.

Tirzepatide improves glycemic control in early-onset type 2 diabetes Tirzepatide enhances insulin sensitivity in type 2 diabetes Tirzepatide improves glycemic control and weight loss in type 2 diabetes Tirzepatide improves glycemic control and weight loss sustainability in type 2 diabetes Tirzepatide improves weight loss in adults with type 2 diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.